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Resumo 
  
O cancro da mama e o cancro do ovário são grupos heterogéneos de doenças 
que podem ser divididas em diferentes subtipos com características específicas e 
respostas distintas ao tratamento utilizado. As mais recentes técnicas de sequenciação 
oferecem, hoje em dia, novas oportunidades para investigar o papel das alterações 
genéticas raras encontradas no cancro da mama e/ou ovário. A proteína fosfatase 
dependente de magnésio isoforma 1D delta (PPM1D), também conhecida como Wip1, é 
uma fosfatase induzida pela TP53, que funciona como um regulador negativo das vias que 
são ativadas em resposta ao “stress” e possui propriedades oncogénicas. Além disso, 
foram recentemente identificadas mutações neste gene associadas a uma predisposição 
para cancro da mama e cancro do ovário. Estas mutações truncantes ocorrem no último 
exão do gene PPM1D e foram descritas em doentes diagnosticados com diferentes tipos 
de cancro, inclusivamente cancro da mama e/ou do ovário. 
Este trabalho teve como objetivos identificar a contribuição das mutações no 
gene PPM1D em mulheres diagnosticadas com cancro da mama e/ou do ovário; 
estabelecer possíveis associações entre alterações no gene PPM1D e características 
clínico-patológicas nesses doentes e correlacionar o estado mutacional com o tratamento 
realizado nestes doentes. Para tal, foi analisada por sequenciação de Sanger a região 
codificante do exão 6 do gene PPM1D, em amostras de sangue periférico de 209 mulheres 
com cancro de mama diagnosticado até aos 35 anos e 117 mulheres com cancro do ovário 
diagnosticado em qualquer idade. 
Foram detetadas três mutações truncantes no gene PPM1D em dois casos com 
cancro do ovário: c.1344_1350del, p (Asn448LysfsTer7); c.1521del, p. (Met508TrpfsTer6); 
e c.1637del, p. (Leu546ArgfsTer2). Estas mutações estão presentes em mosaicismo de 
acordo com a leitura dos electroferogramas da sequenciação. Além disso, foram 
analisadas as respetivas amostras de carcinomas do ovário e não foram encontradas 
mutações, o que é consistente com mosaicismo. Ambos os casos foram tratados com 
quimioterapia, mas apenas num deles o tratamento foi realizado antes da colheita de 
sangue. Para além destas mutações, encontrámos também, na mesma série de cancro do 
ovário, a mutação germinativa missense c.1607G> A, p.Arg536Lys. Nenhuma mutação foi 
encontrada em mulheres diagnosticadas com cancro da mama. 
Conclui-se que as mutações somáticas no gene PPM1D foram encontradas em 
1.7% dos pacientes diagnosticados com cancro do ovário, mas não em pacientes 
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diagnosticados com cancro da mama em idade jovem. Estas mutações foram detetadas 
em células do sangue periférico, mas não em células do respetivo tumor. Dado o limitado 
conhecimento do papel destas mutações na carcinogénese da mama e do ovário, são 
necessários estudos adicionais para compreender as suas eventuais implicações clínicas. 
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Abstract 
 
Both breast and ovarian cancers are heterogeneous groups of diseases, which 
can be divided into several subtypes each having distinct biological and clinical 
characteristics and responses to therapies. Improved sequencing technologies offer 
nowadays an unprecedented opportunity to investigate the role of rare genetic variations in 
breast and ovarian cancer. The protein phosphatase 1D magnesium-dependent delta 
isoform (PPM1D), also known as Wip1, is a TP53-induced phosphatase that functions as a 
negative regulator of stress response pathways and has oncogenic properties. Recently, 
truncating mutations in the last exon of the PPM1D gene have been described in patients 
diagnosed with different types of cancer, including breast and ovarian cancer.  
This work aimed to identify the frequency of PPM1D mutations in early-onset 
breast cancer and in patients diagnosed with ovarian cancer; to establish possible 
associations between PPM1D genetic alterations and clinicopathological features in these 
patients; and to correlate the mutational status with the treatment performed in this patients. 
We performed Sanger sequencing of the coding region of exon 6 in peripheral blood 
samples from 209 women with breast cancer diagnosed until the age of 35 and from 117 
women with ovarian cancer diagnosed at any age. 
Three PPM1D somatic mutations were found in two patients with ovarian 
cancer: the c.1344_1350del, p.(Asn448LysfsTer7); c.1521del, p.(Met508TrpfsTer6); and 
c.1637del, p.(Leu546ArgfsTer2). These mutations appeared to be mosaic according to the 
sequence electropherograms. Additionally, no mutations were found in ovarian tumor 
samples from these two patients, which is also consistent with mosaicism. Both patients 
received treatment with chemotherapy, but only one of them was treated prior to blood 
collection. We also found one patient with ovarian cancer to harbor the non-synonymous 
germline mutation c.1607G>A, p.Arg536Lys. No mutations were found in women diagnosed 
with breast cancer. 
We conclude that somatic PPM1D mutations were found in 1.7% of patients 
diagnosed with ovarian cancer, but not in patients diagnosed with breast cancer at a young 
age. These mutations were detectable in peripheral blood cells, but not in tumor cells from 
these patients. The consequences of PPM1D mutations for breast and ovarian 
carcinogenesis are not yet completely defined and further studies are needed to understand 
the eventual clinical implications of these mutations.
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Introduction 
 
1. Breast and Ovarian Cancer 
 
Cancer causes 1 in 8 deaths worldwide and is rapidly becoming a global 
pandemic. According to the International Agency for Research on Cancer (IARC), there 
were 14.1 million new cancer cases and 8.2 million cancer deaths in 2012. In 2016, the 
National Cancer Institute estimates that 1,685,210 new cancer cases will be diagnosed only 
in the United States and 595,690 people will die from the disease. It is expected that, in 
2030, 21.7 million cases and 13 million deaths will occur (American Cancer Association). 
The future burden of cancer is expected to increase, mainly due to a growing and globally 
aged population combined with risk factors such as smoking, obesity, and dietary patterns 
(Fitzmaurice et al., 2015; Jemal et al., 2010). 
 
1.1. Epidemiology 
 
Breast cancer (BC) is the second most common cancer in the world and, by far, 
the most frequent cancer among women, with 1.67 million new cancer cases estimated to 
be diagnosed in 2012 (25% of all cancers) (IARC Globocan, 2012). BC is the most common 
cause of cancer death in Europe for females, and the third most common cause of cancer 
death overall (IARC Globocan, 2012). 
In terms of incidence worldwide, BC affects women in both developed and 
developing countries, with more cases reported in less developed regions (Figure 1) (Ferlay 
et al., 2015; Jemal et al., 2010). Generally, worldwide trends show that, in developing 
countries going through rapid societal and economic changes, shifting towards lifestyles 
typical of industrialized countries leads to a rising burden of cancers associated with 
reproductive, dietary, and hormonal risk factors (Ferlay et al., 2015; Hulka and Moorman, 
2008). Furthermore, mortality is higher in less developed countries due to a lack of early 
detection and access to treatment facilities (Ferlay et al., 2015). 
Ovarian cancer (OC) is a particularly lethal gynecological malignancy, with a 
survival rate lower than for BC (Jelovac and Armstrong, 2011). OC is the 6th most common 
cause of cancer death in Europe for females, and the 12th most common cause of cancer 
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death overall (Cancer Research UK). According to IARC, in 2012, 238,000 new cases were 
diagnosed (seven times lower than BC). 
OC overall has typically been more incident in industrialized, but nowadays its 
incidence is increasing in low and medium resource countries (Thun et al., 2010), probably 
resulting from adoption of Western patterns such as diet, physical activity, and tobacco use 
(Devita et al., 2011; Ferlay et al., 2015; Stewart, 2012). 
 
Figure 1 - Estimated new cancer cases (incidence) and deaths (mortality) in women in developed and 
developing regions of the world in 2012.  [Adapted from Ferlay J. 2013]. 
 
Portugal follows the same patterns of Europe, concerning incidence and 
mortality rates, with BC ranking 1st in women and OC ranking the 9th in terms of incidence 
(RORENO, 2015). With a female population of 5 million, there are approximately 85,000 
new cases of BC and 8,000 new cases of OC, with an estimated mortality of 18,400 and 
4,400, respectively (Ferlay et al., 2015) (Figure 2). 
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Figure 2 - Estimated incidence and mortality in Portugal, 2012. [Adapted from Ferlay 2013]. 
   
1.2. Risk Factors and Risk Reduction 
 
BC and OC have been attributed to a combination of genetic susceptibility and 
lifestyle factors such as age, reproductive, hormonal and lifestyle features. 
 
 Age: One of the best-documented risk factors for both cancers is age (Feuer 
et al., 1993; Gawron et al., 2012). BC incidence is extremely low before age 30 (incidence 
- 25 cases per 100,000), after which it increases linearly until the age of 80 (Cuny et al., 
2000). Regarding OC, though it may occur at any age, it is more common in patients older 
than 50 years (Roett and Evans, 2009).  
 
 Family history: Family history is one of the most well-established BC risk 
factors. The relative risk of breast cancer conferred by a first degree relative with BC is 2.1 
(Yang et al., 1998). Risk increases with the number of affected relatives, age at diagnosis, 
occurrence of bilateral or multiple ipsilateral BC in a family member, and number of affected 
male relatives (Pharoah et al., 1997). Women with one first-degree and two or more affected 
relatives with OC have a relative risk of 3.1 and 12, respectively (Pharoah and Ponder, 
2002). 
 
85,000
8,200
11,700
12,800
33,900
Incidence
Breast Ovary Lung
Stomach Colorectal
18,400
4,4009,100
9,800
14,900
Mortality
Breast Ovary Lung
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 Genetics: Advances in molecular genetics have led to the identification of 
BRCA1 and BRCA2 gene mutations, which predispose to the hereditary breast-ovarian 
cancer syndrome (HBOC) (Lynch et al., 1994). These two major high-risk susceptibility 
genes are known to be involved in the development of approximately 5-10% of all BC 
(Marchina et al., 2010). The average cumulative risks in BRCA1-mutation carriers, 
unselected for family history, by age 70 years is 55-65% and around 45% for women who 
inherit a BRCA2 mutation (Antoniou et al., 2003).  Other genes such as CHEK2, PTEN, 
TP53, ATM, STK11/LKB1, CDH1, NBS1, RAD50 and PALB2 have been described as high 
or moderate penetrance breast cancer susceptibility genes, all contributing to the hereditary 
breast cancer spectrum (van der Groep et al., 2011). Known susceptibility genes explain 
less than half of the genetic predisposition to BC (Couch et al., 2014).  
Regarding OC risk, a carrier of a BRCA1 or BRCA2 mutation, unselected for 
family history, has an average cumulative lifetime risk of 39% and 11-17% for developing 
OC by the age of 70, respectively (Howlader et al., 2014). Besides HBOC syndrome, which 
represents the majority of these cases (65-85%), other clinical genetic features of hereditary 
OC have been recognized like Lynch syndrome (Lynch et al., 2009; Prat et al., 2005). 
About10-15% of the hereditary cases are associated with germline mutations in the DNA 
mismatch repair (MMR) genes, primarily MLH1 and MSH2 (Lynch et al., 2009; Prat et al., 
2005).  
 
 Reproductive factors: Endogenous female hormones are a well-
established risk factor for BC and OC. The risk of BC is directly related to the time of 
exposure to cycling ovarian hormones (Singletary, 2003). Women who had an early age 
menarche, before age 12, or who had late menopause, after age 55 and null parity have an 
increased risk of developing BC (Hulka and Moorman, 2008).The ovarian epithelium 
responds strongly to the local hormonal environment. Therefore, long-term exposure to high 
elevated hormone levels, early age of menarche and late age at natural menopause 
constitute strong factors capable of increasing the risk for OC (Hunn and Rodriguez, 2012).   
 
 Alcohol consumption: Risk of developing BC increases by 10% for each 
10 g of daily alcohol intake (approximately one drink) in the general population (Smith-
Warner et al., 1998).  There is no evidence that alcohol consumption is associated with 
increased risk for overall OC (Kelemen et al., 2013). 
 
 Oral contraceptives: Oral contraceptives are synthetic versions of estrogen 
and progesterone or progesterone alone. The association between female reproductive 
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organ cancers and use of oral contraceptives has been studied for decades. It has been 
consistently reported that women who have never used them are at a higher risk of 
developing OC. The use of oral contraceptives leads to the decrease in OC risk by 40-50% 
when compared with women who have never been exposed to it (Purdie et al., 1995; 
Rosenberg et al., 1994). This risk reduction occurs even 10 years after discontinuation of 
use (Booth et al., 1989; Rosenberg et al., 1994). It is uncertain whether the use of an oral 
contraceptive increases the risk of BC later in life. (Marchbanks et al., 2012; Robbins SL, 
2010). 
 
1.3. Breast Cancer Pathology and Clinical Features 
 
1.3.1. Histology and Molecular Taxonomy 
 
Breast cancer can be classified into in situ carcinoma or invasive carcinoma. 
The in situ carcinomas may be either lobular (LCIS) or ductal (DCIS), display no invasion 
of the underlying basement membrane, and, consequently, have little potential for 
metastases (Richie and Swanson, 2003). When there is infiltration beyond the basement 
membrane, the malignancy is considered invasive (or infiltrating), being classified into 
several histological subtypes: invasive carcinoma of no special type, invasive lobular 
carcinoma, tubular carcinoma, cribriform carcinoma, mucinous carcinoma, carcinoma with 
medullary features, carcinoma with apocrine differentiation, invasive micropapillary 
carcinoma and metaplastic carcinoma of no special type. Other subtypes which include 
secretory carcinoma and invasive papillary carcinoma, are relatively rare (Lakhani S., 
2012). 
This heterogeneous disease displays a variety of subtypes with different 
expression profiles, which have substantial implications in prognosis and survival rates 
(Carraro et al., 2013). The molecular classification of BC based on gene-expression 
patterns allowed to establish five major breast cancer subtypes: Luminal A, Luminal B, 
Basal-like, HER2-positive, and Claudin-low tumors (Table 1) (Nounou et al., 2015; Prat et 
al., 2010; Schnitt, 2010). These subtypes differ in genomic complexity, key genetic 
alterations and clinical prognosis (Banerji et al., 2012). 
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Table 1 - Molecular subtypes and characteristics of breast cancer. [Adapted from Schnitt S. 2010; Nounou et 
al. 2015]. 
Subtypes Characteristics 
Luminal A Estrogen receptor positive and/or progesterone receptor high, HER2 negative and Ki-
67 protein low (<14%) 
Luminal B Estrogen receptor positive and/or progesterone receptor low, HER2 positive or 
negative, and Ki-67 protein high (>14%) 
Basal-like The majority are estrogen, progesterone and HER2 negative (Triple negative).  
HER2-positive Overexpression of HER2 protein, which is highly associated with HER2 gene 
amplification. Estrogen and progesterone receptors negative 
Claudin-low A more recently described class; often triple negative, with low expression of cell-cell 
junction proteins, including E-cadherin 
 
1.3.2. Diagnosis and Treatment 
 
The underlying principle for BC screening is that it allows the detection of tumors 
at a pre-clinical stage, in order to improve the chance of survival. The European Guidelines 
for quality assurance in BC screening and diagnosis recommends bi-annual mammography 
screening in the age group of 50 to 69 years (Edge and Compton, 2010). Diagnosis of BC 
should be evaluated by triple assessment: a clinical examination, which includes biannual 
palpation, locoregional lymph nodes and assessment for distant metastases; bilateral 
mammography and ultrasound of the breast and regional lymph nodes; and a pathological 
assessment, which should be based on a core needle biopsy (Nounou et al., 2015; Senkus 
et al., 2013). Final pathological diagnosis should be performed according to the World 
Health Organization (WHO) classification and the tumor-node-metastases (TNM) staging 
system. Typically, the histological type, grade, immunohistochemistry (IHC) evaluation of 
estrogen receptor (ER), progesterone (PR) and HER2 receptors status, and measurement 
of proliferative markers such as Ki-67, are taken into consideration (Senkus et al., 2015). 
HER2 gene amplification status may be assessed through use of in situ hybridization 
(fluorescent or chromogenic or silver in situ hybridization), hence replacing IHC, or in 
combination for tumors with an ambiguous (2+) IHC score (Senkus et al., 2015; Senkus et 
al., 2013). 
Breast cancer is usually treated through combinations of different therapies, 
such as surgery, radiation therapy, chemotherapy, hormone therapy and targeted therapy: 
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 Surgery: Breast-conserving surgery is the most common approach in the 
treatment of localized breast cancer, primarily used in 60 to 80% of cancers diagnosed in 
Central Europe. However, in some patients mastectomy is still carried out because of tumor 
size (relative to breast size), tumor multicentricity, inability to obtain negative surgical 
margins after multiple resections, prior radiation to the chest wall or breast, other 
contraindications to radiation therapy, or even by patient choice (Nounou et al., 2015; 
Senkus et al., 2013). 
 
 Endocrine treatment:  For premenopausal patients, treatment with 
Tamoxifen (ER antagonist) seems to be particularly beneficial (Senkus et al., 2015). It 
improves the overall survival by almost 50% and breast cancer specific survival by one third 
during the first 5 years (Early Breast Cancer Trialists' Collaborative et al., 2011). For 
postmenopausal patients, treatment with aromatase inhibitors (AI) and tamoxifen are valid 
options (Nounou et al., 2015). 
 
 Targeted therapy: Trastuzumab is a monoclonal antibody that binds to 
HER2 present on the cell membrane. Such approach has shown to decrease mortality in 
women with amplified HER2, in both metastatic and primary disease (Baselga et al., 2006; 
Slamon et al., 2001). Once taken together with chemotherapy, it can reduce mortality 
relative risk by 34% (Moja et al., 2012). Recently, other drugs targeting HER2 have become 
available, for instance pertuzumab, which inhibits receptor dimerization (Agus et al., 2002). 
HER2 overexpression can also be targeted by the small molecule lapatinib, which inhibits 
the tyrosine kinase function of the receptor (Wood et al., 2004).  
 
 Radiotherapy: Postoperative RT is strongly recommended for patients with 
BC (Senkus et al., 2015). Whole breast radiation therapy reduces the risk of local recurrence 
and has been shown to have a beneficial effect on survival (Senkus et al., 2015). The benefit 
of radiotherapy is most evident in women with higher risk of recurrence, decreasing the 
recurrence risk by 20% over 10 years (Kurtz and Party, 2002). 
 
 Chemotherapy: The benefit from chemotherapy is more pronounced in ER-
negative tumors (Senkus et al., 2013). According to the NCCN guidelines, there are several 
types of chemotherapy: the most common combinations in breast cancer are doxorubicin 
and cyclophosphamide with paclitaxel; and docetaxel plus cyclophosphamide. Other 
regiments included in the guidelines are epirubicin with cyclophosphamide, 
cyclophosphamide, methotrexate with fluorouracil; fluorouracil and doxorubicin plus 
cyclophosphamide; or docetaxel, doxorubicin with cyclophosphamide (NCCN, 2016a). 
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These compounds target vital elements in dividing cells, thus inhibiting proliferation and 
increasing apoptosis. Effective results are more evident in highly proliferating tumors (van 
der Hage et al., 2001).  The decision on systemic adjuvant therapies should be based on 
the molecular classification (Table 3). All luminal cancers should be treated with endocrine 
therapy, since they are ER positive (Senkus et al., 2015). Most luminal A tumors require no 
chemotherapy, except those with highest risk of relapse. Similarly, indications for 
chemotherapy within luminal B HER2 negative tumors depend on the risk of relapse (taking 
into account the tumor extent, grade, cell proliferation and vascular invasion), presumed 
responsiveness to endocrine therapy and patient choice. Luminal B HER2 positive tumors 
are frequently treated with chemotherapy, endocrine therapy and trastuzumab, whereas in 
triple-negative tumors, chemotherapy is the main approach. As for HER2 positive tumors, 
chemotherapy coupled with trastuzumab is the most common option (Nounou et al., 2015). 
  
Adjuvant therapy 
strategies for 
breast cancer
Luminal A
ET (ChT is only 
considered in 
selected high risk 
cases)
Luminal B
HER2 
positive
ET+ ChT + 
Anti-HER2
HER2 
negative
ET+ ChT for 
the majority of 
cases
HER2 
positive
ChT + 
Anti-
HER2
Triple 
negative
ChT
Figure 3 - Adjuvant therapy options according to the molecular subtypes. HER2, human epidermal growth 
factor 2 receptor; ChT, chemotherapy; ET, endocrine therapy. [Adapted from Nounou et al., 2015]. 
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1.4. Ovarian Cancer Pathology and Clinical Features 
 
1.4.1. Histology and Molecular Taxonomy 
 
According to The American Joint Committee on Cancer (AJCC), clinicians 
should use the histologic typing of malignant ovarian tumors as recommended by the World 
Health Organization (WHO). There are three main histologic types of ovarian carcinoma 
that are sufficiently distinct and well-characterized: epithelial tumors, sex-cord stromal 
tumors, and germ cell tumors. Tumors of each of these groups can be benign or malignant. 
Malignant germ cell tumors are rare and occur mainly in children and young women. 
Malignant stromal tumors occur at all ages and are also uncommon. There are different 
subtypes of carcinoma in the epithelial group: serous (80%), transitional cell (10-15%), 
endometrioid (10%), clear cell (5%), mixed epithelial tumors (<10%), mucinous carcinoma 
(3%), undifferentiated and unclassified tumors (Ledermann et al., 2013) (Table 2). Over the 
last decade, it has become clear that these are not simply morphologic variants, but actually 
reflect different diseases. This is based on major differences in clinical, pathological and 
molecular features (Seidman, 2014). 
One group of tumors, designated type I, is composed of low grade tumors, 
including low grade serous, low grade endometrioid, clear cell and mucinous carcinomas 
(Gurung et al., 2013). The majority of these tumors are indolent, genetically stable and seem 
to be confined to the ovary. They lack TP53 mutations, but each histologic type exhibits a 
distinctive molecular genetic profile. For example, two thirds of low-grade serous 
carcinomas present KRAS, BRAF, and HER2 mutations (Kurman and Shih Ie, 2010). In 
contrast, another group of tumors, designated type II, are highly aggressive, evolve rapidly 
and are predominantly present in advanced stages. Type II tumors include conventional 
high-grade serous carcinoma, high-grade endometrioid and malignant mixed mesodermal 
tumors (carcinosarcomas). Over 80% of these cases present mutations in the TP53 gene, 
but lack mutations in the genes commonly mutated in type I tumors (Kurman and Shih Ie, 
2016). 
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Table 2 - Histological and molecular classification of ovarian cancer. [Adapted from Ledermann et al. 2013]. 
Ovarian Cancer 
Histological Classification Molecular Classification 
- Serous 
- Endometrioid 
- Mucinous 
- Clear cell  
- Mixed epithelial 
- Unclassified  
- Undifferentiated 
Type I: 
Low grade serous carcinoma (<5%) 
Low grade endometrioid carcinoma (~5%) 
Mucinous carcinoma (3%) 
Clear cell carcinoma (10%) 
Type II: 
High grade serous carcinoma (70%) 
High grade endometrioid carcinoma (~5%) 
 
1.4.2. Diagnosis and Treatment 
 
After full clinical assessment, measurement of serum CA 125 is routinely used 
to aid diagnosis. However, its utility to detect early disease is questionable as it is highly 
expressed in only 50% of patients with stage I disease (Holschneider and Berek, 2000). 
Ultrasonography of the abdomen and pelvis is usually the first imaging investigation 
recommended for women suspected to have OC. Transvaginal ultrasonography has 
improved the visualization of ovarian structures, thus improving the differentiation of 
malignant versus benign conditions (Lerner et al., 1994). Computed tomography scans are 
routinely used to determine the extent of disease and to aid in surgical planning. OCs are 
also graded and FIGO is the most common system. The carcinoma grade does not add any 
prognostic value in cases where the histological type has been carefully assessed using the 
WHO diagnostic criteria and is mainly used for distinguish between high and low grade 
serous carcinomas (Ledermann et al., 2013). 
The standard treatment of OC is based on a combination of cytoreductive 
surgery and chemotherapy.  
 
 Surgery:  Primary treatment for OC, according to the NCCN guidelines, 
consists of surgical staging and cytoreduction (NCCN, 2016b). Initial surgery should be 
staging laparotomy to resect the tumor and to undertake adequate staging. This will provide 
prognostic information and will define whether chemotherapy is needed (Ledermann et al., 
2013). For young patients diagnosed with unilateral stage I tumors, a unilateral salpingo-
oophorectomy may be adequate to preserve fertility (NCCN, 2016b).  In advanced epithelial 
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ovarian cancer, the treatment established is complete cytoreduction of all macroscopic 
disease, since this has been shown to be associated with a significantly increased overall 
survival and progression-free survival (Ledermann et al., 2013; NCCN, 2016b). 
 
 Target therapy: PARP inhibitors represent novel therapeutic tools for  
homologous recombination (HR) deficient tumor, BRCA mutation carriers and recurrent 
platinum-sensitive OC (Gadducci and Guerrieri, 2016). PARP [Poly (adp-ribose) 
polymerase] inhibitors are involved in base excision repair (BER), a major DNA-repair 
pathway. Olaparib is an oral PARP inhibitor that has shown effect in ovarian  tumors with 
known BRCA mutations and is approved since 2014, according to the  U.S. Food and Drug 
Administration (FDA) (Meehan and Chen, 2016). The genetic interaction between PARP 
and BRCA can be described as synthetic lethal. Synthetic lethality between two genes 
occurs where individual loss of either gene is compatible with life, but simultaneous loss of 
both genes results in cell death. It has for a long time been suggested that a synthetic lethal 
approach could be used in the treatment of cancer (Hartwell et al., 1997). PARP-BRCA 
interaction provides the first example of a successful synthetic lethal approach that is used 
in the clinic (Helleday, 2011). Besides Olaparib, other PARP inhibitors, like Veliparib, 
Rucaparib, Niraparib and Talazoparib, have been tested in OC with promising results 
(Meehan and Chen, 2016). Bevacizumab is also used in combination with paclitaxel or 
carboplatin (Ledermann et al., 2013). 
 
 Chemotherapy: The risks of disease recurrence or disease spread beyond 
the ovary are significant, and chemotherapy is frequently recommended for all patients with 
advanced disease post-surgery. According to the NCCN guidelines, observation is 
recommended for patients with stage I, but some clinical studies recommend administration 
of chemotherapy in early-stage ovarian cancer (Winter-Roach et al., 2009). Compared with 
intravenous treatment, intraperitoneal administration has demonstrated a survival 
advantage when incorporated with the upfront management for OC (Markman, 2016). The 
intraperitoneal regimen recommended by the NCCN panel is paclitaxel combined with 
cisplatin (NCCN, 2016b). Standard intravenous regimens consists of a combination of 
paclitaxel and carboplatin or a combination of docetaxel with carboplatin (Ledermann et al., 
2013; NCCN, 2016b). 
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 2. Genetics of Cancer 
 
2.1. Breast Carcinogenesis 
 
Several models of breast carcinogenesis have been proposed, but the most 
accepted are the multistep model of BC and the “theory of parallel disease” (Wiechmann 
and Kuerer, 2008). In the first model, low grade DCIS progresses through sequential stages, 
from premalignant hyperplastic breast lesion, with and without atypia (atypical ductal 
hyperplasia, atypical lobular hyperplasia and usual ductal hyperplasia), to carcinoma in situ 
(ductal or lobular) and then to invasive carcinoma (IBC) (Dupont et al., 1993; Wiechmann 
and Kuerer, 2008). However, the correlation between premalignant lesions and invasive 
carcinoma is still not clear (Wiechmann and Kuerer, 2008). The second model hypothesizes 
that low grade DCIS tends to progress to low grade IBC, and high grade DCIS tends to 
progress to high grade IBC (Figure 4) (Lopez-Garcia et al., 2010; Wiechmann and Kuerer, 
2008).  
 
 
 
2.2. Ovarian Carcinogenesis 
 
The cell of origin for OC and the mechanisms by which cancer develops have 
been long debated (Kurman and Shih Ie, 2016). Until recently, the incessant ovulation 
theory put forward by Fathalla in 1971 has been the most widely accepted theory and it 
Figure 4 - Classification of ductal carcinoma in situ based on biologic potential to progress to invasive 
breast cancer. [Adapted from Wiechmann and Kuerer, 2008]. 
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states that a constant ovulation-induced damage and repair of the ovarian surface 
epithelium eventually results in its malignant transformation to ovarian epithelial cancers. 
However, several morphologic, epidemiologic, and molecular observations have gradually 
accumulated over the decades and, at the present time, the ovarian surface epithelium is 
not considered to be the cell of origin of ovarian epithelial cancers by most researchers 
(Chen et al., 2013; Erickson et al., 2013; Kurman and Shih Ie, 2016; Li et al., 2011; Reade 
et al., 2014). The reasons include histologic and immunophenotypic differences between 
ovarian surface epithelium and ovarian epithelial cancers and the presence of precancerous 
lesions of high grade serous carcinomas in tubal fimbria but not in the ovary (Carlson et al., 
2008; Fathalla, 2013; Li et al., 2011). The most recent evidence suggests that the vast 
majority of what appear to be primary ovarian cancers, namely serous, endometrioid and 
clear cell carcinomas, are derived from the fallopian tube and endometrium, not directly 
from the ovary (Kurman and Shih Ie, 2016).  
 
2.3. Genetic and Epigenetic Alterations 
 
2.3.1. Tumor Suppressor Genes 
 
A tumor suppressor gene is a gene whose alteration during carcinogenesis 
results in the loss of a functional property essential for the maintenance of normal cell 
proliferation. Loss of function of a tumor suppressor gene is typically a recessive 
mechanism. Indeed, in many instances both copies of the gene need to be inactivated in 
order to switch off the corresponding function (Oliveira et al., 2005). 
One of the most well-known tumor suppressor genes is TP53, which is mutated 
in more than half of all human cancers (Vousden and Lu, 2002). In its active form, TP53 
triggers the transcription of various target genes that induce cell cycle arrest, DNA repair, 
senescence, and apoptosis. These effects ultimately either promote the repair and survival 
or the permanent removal of damaged cells (Vousden and Prives, 2009). In both BC and 
OC, TP53 mutations have been associated with worse prognosis and increase of the 
relative risk of relapse (Osborne et al., 2004). 
BRCA1 and BRCA2 are by far the two most common tumor suppressor genes 
associated with predisposition to breast and ovarian cancer (Devita et al., 2011). The 
functions of BRCA1 and BRCA2 are involved in two fundamental cellular processes: DNA 
damage repair and transcriptional regulation (Welcsh and King, 2001). 
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2.3.2. Oncogenes 
 
Oncogenes are derived from proto-oncogenes, which are genes that encode 
regulatory proteins of the cell that are involved in cell differentiation and cell-signaling 
pathways (Kierszenbaum and Tres, 2002). Their activation can occur by point mutations, 
amplifications, or chromosomal rearrangements (Croce, 2008). Compared to tumor 
suppressor genes, an oncogenic activating somatic mutation in one allele is generally 
sufficient to confer a selective growth advantage on the cell (Vogelstein and Kinzler, 2004). 
An example is the HER2 amplification, with resultant HER2 protein overexpression that has 
been shown to play a role in multiple cancer pathways, such as sustaining angiogenesis, 
increasing cell division and enhancing invasion and metastization (Slamon et al., 2011).  In 
OC the amplification of the RAS-related protein (Rab25), which belongs to the RAS family, 
is usually amplified and upregulated in most OCs and regulates motility, aggressiveness, 
apoptosis and autophagy (Bast et al., 2009).  
 
2.3.3. Epigenetic Alterations 
 
Epigenetics is defined as changes in gene activity and expression that occur 
without alteration in DNA sequence (Goldberg et al., 2007). DNA hypomethylation can be 
associated with gene reactivation and might lead to the upregulation or overexpression of 
proto-oncogenes. DNA hypermethylation is frequently associated with gene repression, 
compaction of chromatin and genomic instability that lead to suppression of tumor 
suppressor genes. Breast tumors are frequently hypomethylated on a genome-wide scale, 
but the number of genes described as hypomethylated in BC and OC is relatively small 
(Jovanovic et al., 2010). The endonuclease FEN1, the N-acetyltransferase NAT1 and the 
cadherin CDH3 are examples of genes that are hypomethylated in primary breast tumors 
(Jovanovic et al., 2010). On the other hand, more than a hundred genes have been reported 
to be hypermethylated in breast tumors. BRCA1, APC and BCL2 are examples of genes 
that are silenced by hypermethylation in BC (Jovanovic et al., 2010; Stefansson and 
Esteller, 2013). Tumor suppressor genes that are usually hypermethylated in OC are 
BRCA1, TP16 and MLH1 (Strathdee et al., 2001).  
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2.4. Genetic Predisposition to Breast and Ovarian Cancer 
 
The genetic predisposition to BC and OC has been well established. Up to 10% 
of all BCs and up to 15% of all OCs are caused by inherited genetic defects (Lynch et al., 
2009). Some cancer predisposition syndromes that confer a higher risk of developing breast 
cancer have been described, and include HBOC, hereditary diffuse gastric cancer, Cowden,  
Peutz-Jeghers, and Li-Fraumeni syndromes. These syndromes are caused by mutations in 
the BRCA1/2, CDH1, PTEN, STK11, and TP53 genes, respectively  (Apostolou and Fostira, 
2013; Easton et al., 2015). In OC, approximately 90% of the genetic predisposition is 
explained by gene defects in the high penetrance genes BRCA1/2, whereas the remaining 
10% of the genetic predisposition is attributable to defects in MMR genes (Prat et al., 2005). 
  
 
2.4.1. Pathogenic BRCA1/2 Germline Mutations 
 
Genetic testing for BRCA1/2 mutations in individuals with a personal and family 
history of BC or OC is an important tool in determining appropriate clinical management 
(Domchek and Weber, 2008). The pathogenicity of many changes in BRCA1/2 genes and 
other disease-associated genes can be predicted from the nature of the mutation. Large 
deletions, frameshifts and nonsense mutations that cause loss of important functional 
domains or result in unstable transcripts, can be classified with reasonable confidence as 
loss-of-function mutations (Chenevix-Trench et al., 2006). However, about 20% of the 
germline changes found in BRCA1/2 are missense variants of unknown pathogenic 
potential, termed variants of uncertain significance (VUS) (Domchek and Weber, 2008).  
 
2.4.2. Identification of Families with BRCA1/2 Mutations 
 
Individuals with a germline mutation in the BRCA1/2 genes have a very high 
cumulative risk of developing BC and/or OC, so it is essential to identify the families that 
carry these mutations (Antoniou et al., 2003).  
The identification of specific and recurrent/founder mutations in any given 
population allows a more efficient and cost-saving mutational screening approach. Peixoto 
et al. (2015) recommends the screening of the most recurrent and/or founder mutations in 
Portuguese patients, by a multiplex PCR method that allows the simultaneously detection 
of the two most frequent mutations in Portuguese HBOC families (BRCA2 c.156_157insAlu 
and BRCA1 c.3331_3334del). Furthermore, they report that the screening of the entire 
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coding regions of BRCA1/2 should subsequently be offered to those families with a mutation 
probability ≥10%, if no founder mutation is found (Peixoto et al., 2015). The recommended 
clinical criteria to offer genetic testing of the most common BRCA1/2 mutations to an 
affected proband in Portuguese HBOC families are listed in Table 3. 
 
Table 3 - Clinical criteria in Portuguese patients for genetic testing of the most common BRCA1/2 mutations 
even if a priori mutation probability is <10%. [Adapted from Peixoto et al., 2015]. 
 
 
2.5. The PPM1D Gene 
 
2.5.1. The Role of PPM1D 
 
The PPM1D gene encodes a protein phosphatase magnesium-dependent delta 
isoform (PPM1D, also known as Wip1), and was first described by Fiscella and 
collaborators in 1997 (Fiscella et al., 1997). The PPM1D gene encodes a serine/threonine 
phosphatase that displays typical characteristics of evolutionary conserved type 2C protein 
phosphatases (PP2C) family (Choi et al., 2000; Fiscella et al., 1997). The PP2C-family 
members have previously been implicated in stress protection, sexual differentiation, and 
cell cycle regulation (Choi et al., 2000). Takekawa and his colleagues identified the first 
target of PPM1D, the p-38 mitogen-activated protein kinase (p38 MAP kinase) (Takekawa 
et al., 2000). Genotoxic stress such as UV radiation causes activation of p38 MAP kinase 
by phosphorylation and consequently phosphorylates TP53 (Bulavin et al., 2002; Choi et 
al., 2000), increasing TP53 activity, including gene transcription and apoptosis (Lu et al., 
2005). On the other hand, PPM1D is induced after DNA damage and consecutively 
inactivates p38 through dephosphorylation. This will attenuate UV-induced phosphorylation 
of TP53-mediated transcription and apoptosis (Takekawa et al., 2000). Thus, PPM1D 
- Any breast cancer patient diagnosed until the age of 35 (or 40 in case of a triple 
negative or medullary carcinoma); 
- Two first/second degree relatives with breast or ovarian cancer, at least one 
diagnosed before the age of 50 (or pancreatic cancer at any age); 
- Three first/second degree relatives with breast, ovarian or pancreatic cancer at any 
age; 
- Any male breast cancer case should be tested for the BRCA2 c.156_157insAlu 
founder mutation. 
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inhibits UV-induced phosphorylation of TP53 via p38 downregulation, functioning as a 
mediator in a TP53 negative feedback regulatory loop (Lu et al., 2005) (Figure 5). 
 
 
 
 
  
  
Figure 5 - PPM1D transcription is upregulated (blue arrow) in response to various types of DNA damage in a 
p53-dependent manner. Once upregulated, PPM1D dephosphorylate (red arrow) p38 MAP kinase protein and 
consequently suppresses TP53 activity. [Adapted from (Ruark et al., 2013)]. 
 
The PPM1D gene is located in the chromosomal region 17q23 and encodes a 
605 amino acid protein that is subdivided in two major domains: a highly conserved N-
terminal phosphatase domain comprising amino acids 1-375 and a less conserved non-
catalytic domain extending from amino acids 376-605 comprising a nuclear localization 
signal (Lu et al., 2005) (Figure 6). 
 
Figure 6 - PPM1D gene with region targeted by mutations (mutation cluster region) in blue (upper image); 
PPM1D protein showing position of mutation cluster region downstream of the phosphatase domain and 
upstream/overlapping the nuclear localization signal (NLS) (bottom image). [Adapted from Ruark et al., 2013]. 
  
PPM1D 
DNA Damage 
p38 MAP kinase TP53 
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2.5.2. PPM1D Somatic Alterations in Tumors 
 
Amplification and overexpression of the PPM1D gene has been reported in 
different primary human cancers, mainly breast (11-16%) (Li et al., 2002; Rauta et al., 2006), 
ovarian (Tan et al., 2009), gastric (Ma et al., 2014) and neuroblastoma (Saito-Ohara et al., 
2003), conferring a poor clinical outcome. PPM1D is also able to complement the effect of 
other oncogenes in cellular transformation, such as RAS, MYC and HER2 (Bulavin et al., 
2004; Li et al., 2002). Expression of PPM1D was also reported as a novel prognostic marker 
for the survival of patients with lung cancer (Satoh et al., 2011; Yang et al., 2015). Yang et 
al demonstrated that overexpression of PPM1D was positively associated with progression 
and poor prognosis in patients with non-small cell lung cancer (NSCLC) (Yang et al., 2015).  
In addition to gene amplification and overexpression, potentially cancer-driving 
mutations have also been identified in the PPM1D gene. Zhang and his collaborators 
detected somatic mutations in the PPM1D gene in DNA extracted from tumor samples, by 
whole-exome sequencing in brainstem gliomas (BSGs) (Zhang et al., 2014). All of the 
mutations found were truncating mutations in exon 6 and always co-occurred with mutations 
in the histone gene H3F3A, which characterizes a specific subgroup of pediatric 
glioblastoma with a very poor prognosis. H3F3A mutated BSGs contained either a PPM1D 
or a TP53 mutation in a completely mutually exclusive fashion, which suggests that TP53 
and PPM1D mutations may have equivalent oncogenic functions in this disease (Zhang et 
al., 2014). An important exception to these gain-of-function truncating PPM1D mutations is 
the frequently found R552X-truncating mutation, which is a loss-of-function mutation and is 
associated with a decrease in protein stability (Dudgeon et al., 2013; Emelyanov and 
Bulavin, 2015). The same authors also reported three germline PPM1D missense mutations 
in the phosphatase domain that contributed to loss-of-function and, as such, resulted in 
upregulation of TP53 activity (Dudgeon et al., 2013). Germline missense mutations have 
recently been reported as having a possible role in prostatic cancer predisposition (Cardoso 
et al., 2016). 
 
 
2.5.3. PPM1D Mosaic Mutations 
 
Recently, PPM1D mosaic truncating mutations were described in breast and 
ovarian cancer (Ruark et al., 2013; Akbari et al., 2014), non-small cell lung cancer 
(Zajkowicz et al., 2015) and prostate cancer (Cardoso et al., 2016) patients, suggesting that 
these mutations might be associated with a wide range of cancers.  
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Two studies have related PPM1D mutations in mosaicism with a higher 
predisposition to BC and OC (Akbari et al., 2014; Ruark et al., 2013). In 2013, Ruark et al. 
sequenced 507 genes implicated in DNA repair and reported a frequency of 0.26% and 
1.07% of PPM1D truncating mutations in patients with BC and OC, respectively, estimating 
that the relative risk of a PPM1D mutation carrier for BC and OC was 2.7 and 11.5, 
respectively (Ruark et al., 2013). After analyzing the chromatograms, they observed that 
the truncating variants were unusual for heterozygous mutations as the mutant allele was 
considerably and consistently lower than the wild type. After confirming these results using 
two different detection methods, deep PCR amplicon sequencing and multiplex ligation-
dependent probe amplification (MLPA), they classified these variants as being mosaic. 
Furthermore, they found these mutations in DNA from peripheral blood cells, but not in the 
respective tumors (Ruark et al., 2013). Later on, Akbari et al. described similar results, 
reporting mosaic PPM1D mutations in DNA from peripheral blood cells but not in DNA from 
the tumor (Akbari et al., 2014).  
All the PPM1D truncating mutations reported in these two works are located in 
the last exon of the gene (exon 6), in the C-terminal domain downstream of the catalytic 
domain. This indicates that these mutations are not acting as typical loss-of-function 
mutations, resulting instead in an increased stability and preserved enzymatic activity 
(Akbari et al., 2014; Ruark et al., 2013). Moreover, functional studies revealed that these 
variants enhance TP53 suppression after exposure to ionizing radiation, which suggests 
that these mutations confer gain-of-function (Emelyanov and Bulavin, 2015; Kleiblova et al., 
2013). Furthermore, since they are all located in the last exon of the gene, it is plausible 
that the mutated transcripts could evade nonsense-mediated mRNA decay (Ruark et al., 
2013).  
Recently, two articles suggested that chemotherapy exposure could influence 
the accumulation of these mutations (Pharoah et al., 2016; Swisher et al., 2016). To test 
this theory, the authors performed parallel sequencing to quantitate mutations in the 
peripheral blood mononuclear cells of women with primary OC or relapsed platinum-
resistant OC and reported that women with relapsed OC, receiving two or more 
chemotherapy treatments, had an increased number of somatic mosaic PPM1D mutations 
(Pharoah et al., 2016; Swisher et al., 2016). However, the data are still scarce and further 
studies are required to explain the mechanism of origin and pathogenetic relevance of 
PPM1D mutations. 
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Aims 
 
 
The general aim of this work was to evaluate the role of PPM1D mutations in 
patients with breast and ovarian cancer. Specifically, the objectives of this thesis were: 
 To determine the prevalence of PPM1D mutations in patients with early-onset 
breast cancer and in patients diagnosed with ovarian cancer;  
 To look for associations between PPM1D genetic alterations and 
clinicopathological features; 
 To correlate the mutational status of the PPM1D gene with the treatment 
performed, more specifically with chemotherapy exposure. 
 
  
 
 
 
 
 
 
 
 
 
Material and Methods 
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Material and Methods 
 
1. Clinical Samples 
 
A series of DNA samples from 326 patients, 209 diagnosed with BC and 117 
diagnosed with OC, were retrospectively analyzed. These patients were referred to the IPO-
Porto Genetics Department for BRCA1/2 genetic testing, between June 2006 and February 
2015 and were selected for this study according to the following criteria: 
1. Women diagnosed with breast cancer younger than 36 years old, with no 
family history of breast cancer and/or ovarian cancer and negative for 
deleterious BRCA1/2 mutations (BC; 209 cases) by either founder mutation 
(179 cases) or full gene testing (30 cases). 
2. Women diagnosed with OC (117 cases), of which 80 were negative for 
BRCA1/2 mutations by founder mutation testing (48 cases) or full gene 
analysis (32 cases), 28 had a BRCA1/2 pathogenic mutation, and nine had 
a variant of uncertain significance (VUS) in the BRCA1/2 genes (Table 4).  
Clinical data was obtained from clinical records and this study was approved by 
the institutional review board of the Portuguese Oncology Institute of Porto.  The mean age 
at diagnosis was 32 years for female BC and 48 years for OC. Ovarian carcinoma were 48 
serous, 16 endometrioid, 10 clear cells, 9 mucinous, 2 mixed epithelial and 3 
undifferentiated. Breast carcinoma were 137 invasive ductal, 12 mixes type, 8 DCIS, 6 
invasive lobular, 2 mucinous and 1 with medullary features. Regarding therapy, 98% of OC 
and 91% of BC patients were treated with chemotherapy.  
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Table 4 - BRCA1 and BRCA2 mutations detected in patients diagnosed with ovarian cancer. 
B
R
C
A
1
 
 Mutation Protein Case 
Number 
 Pathogenic 
 c.4136_4137del p.(Ser1379Ter) #5 
 c.441+1724_oNBR1:c.1073+480del p.?  #40 
 c.470_471del p.(Ser157Ter) #34; #107 
 c.1488del p.(Leu498SerfsTer5) #106 
 c.2086dup p.(Thr696AsnfsTer16) #52 
 c.2418del p.(Ala807HisfsTer8) #49; #89 
 c.2490_2497dup p.(Leu833CysfsTer16) #24 
 c.2906del p.(Asn969IlefsTer31) #44 
 c.3331_3334del p.(Lys1111AsnfsTer5) #42; #51; 
#75; #80; #28 
 c.3477_3480del p.(IIe1159MetfsTer50) #84 
 c.4035del p.(Glu1346LysfsTer20) #41 
 c.2037delinsCC p.(Lys679AsnfsTer4) #23 
 c.5030_5033del p.(Thr1677llefsTer2) #64 
 c.5278-1G>T   #63 
 VUS 
 c.5122G>C p.(Ala1708Pro) #9 
 c.80+5G>C   #32 
 c.2458A>G p.(Lys820Glu) #58 
B
R
C
A
2
 
 Pathogenic 
 c.5355dup p.(Ser1786Ter)  #7  
 c.156_157insAlu   #29; #33; 
#56; #92; 
#96; #104 
 c.6347A>G p.(His2116Arg) #12 
 VUS 
 c.2803G>A p.(Asp935Asn) #21 
 c.8525G>T p.(Arg2842Leu) #37 
 c.10234A>G p.(Ile3412Val) #57 
 c.5199C>T  p.(Ser1733=) #68 
 c.8850G>T p.(Lys2950Asn) #68 
 c.3516G>A p.(Ser1172=) #109 
 c.8036A>G p.(Asp1679Gly) #112 
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2. DNA Extraction and Quantification from Blood 
 
Peripheral blood samples were collected in sterile tubes containing EDTA 
anticoagulant. In order to achieve the lysis of erythrocytes, a hypotonic solution was added 
(AKE: NH4Cl [Merck, Darmstadt, Germany] 155 mM; KHCO3 [Merck] 10 mM; EDTA [Sigma-Aldrich, Steinheim, 
Germany] 0.1 mM; pH=7.4) to 3-5 mL of blood in a ratio of 9 to 10 times this volume, followed 
by incubation on ice for 30 minutes. The samples were then centrifuged at 1500g [Sigma 
centrifuge 4K15]. The supernatant was removed and the procedure was repeated as described 
above until the pellet was free of hemoglobin. The cell pellet was resuspended in 1 mL of 
PBS [Merck], transferred to a microcentrifuge tube and centrifuged at 3000g. The supernatant 
was removed and the cell pellet was stored at -80°C.  
DNA was obtained using the Magna Pure LC 2.0 [Roche Applied Science, Indianapolis, Indiana], 
according to the manufacturer’s instructions (Chomczynski, 1993). DNA quality and 
concentration was evaluated using a NanoDrop ND-1000® [NanoDrop Technologies, Wilmington, DE, USA]. 
 
3. DNA Extraction from Formalin-fixed Paraffin-embedded 
Tissue  
 
Tumor areas containing at least 50% of tumor cells were delimited, by a 
pathologist, in the hematoxylin and eosin (H&E) stained slides of each sample. The 
corresponding unstained slides were immersed in xylene [Sigma] and twice in ethanol 100% 
[Merck] for 5 minutes each. Tumor and normal areas, which were previously delimited by 
comparison with the correspondent H&E stained slides, were macrodissected and 
transferred to a centrifuge tube. DNA was isolated using the QIAamp® DNA FFPE Tissue 
Kit [Qiagen, Hilden, Germany], following manufacturer’s instructions. Finally, DNA was quantified by 
spectrophotometry with NanoDrop ND-1000®. 
 
4. DNA Sequencing 
 
Mutation screening of PPM1D exon 6 was performed by Sanger sequencing 
(Sanger et al., 1977). For this purpose, 20 ng of DNA were amplified using a PCR reaction 
containing 1x Taq reaction buffer (75 mM Tris-HCl, 20 mM (NH4)2SO4) [Thermo Fisher Scientific, 
Rockford, USA, 2 mM of MgCl2 [Thermo Fisher Scientific Rockford, USA], 0,5 mM dNTP mix [Applied Biosystems, Foster 
City, CA, USA], 0,25 mM of each primer (forward and reverse) [Frilabo, Portugal], 1U of Taq DNA 
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polymerase [Thermo Fisher Scientific, Rockford, USA], ] and bidistilled sterile water [B. Braun, Foster City, CA, 
USA]  in a final reaction volume of 20 μL. 
Specific primer pairs were designed using the Primer-BLAST design tool from 
the National Center for Biotechnology Information (NCBI). The following set of primer were 
used: Forward 5´-GTGAATGCATACCCCGTTT-3´ and Reverse 5´-
TCGGCACCAAATTTAAAAAG-3´. PCR reaction was performed according to the conditions 
described in Table 5. 
 
Table 5 - PCR program used for the amplification of exon 6 of the PPM1D gene. 
Temperature Time Step 
95ºC 15 minutes Initial Denaturation 
95ºC 30 seconds Denaturation 
56ºC                     30 seconds           34x Annealing 
72ºC 45 seconds Extension 
72ºC 9 minutes Final Extension 
4ºC undetermined Pause 
 
Amplified PCR products were analysed by electrophoresis in a 2% (w/v) 
agarose gel [Gibco Invitrogen] stained with green safe [Sigma-Aldrich] 0.05 μL/mL. In order to remove 
salt, enzymes, nucleotides and non-incorporated primers, the PCR products were purified 
using the ExoSAP-IT method, according to the manufacturer´s protocol. Briefly, samples 
were purified by adding 2 μL of ExoSAP solution (Exonuclease I [Thermo Fisher Scientific] (20 U/μL) 
and Fast Thermosensitive Alkaline Phosphatase [Thermo Fisher Scientific] (1 U/μL), in a proportion 
of 1:2) to 5 μL of the PCR product, followed by an incubation at 37ºC for 50 minutes, and 
enzyme inactivation at 80ºC for 15 minutes. The product length was 747 bp.  
Sanger sequencing was performed using BigDye Terminator v3.1 Cycle 
Sequencing Kit [Applied Biosystems, Foster City, CA, USA], following the manufacturer´s instructions. The 
reaction was performed using 3.4 μL of sequencing buffer, 0.5 μL of Big Dye® Terminator 
v3.1, containing dNTPs, ddNTPs-fluorocromes, MgCl2 and Tris-HCl buffer, 0.32 μL of a 
10mM primer solution, 1 μL of the previously purified DNA and bidistilled sterile water [B. 
Braun] to reach a final reaction volume of 10 μL. Sequencing reaction was completed using 
the conditions presented in Table 6. 
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Table 6 - PCR program of sequencing reaction. 
Temperature Time Step 
95ºC 4 minutes Initial Denaturation 
95ºC 10 seconds Denaturation 
50ºC 10 seconds 34x Annealing 
60ºC 2 minutes Extension 
60ºC 10 minutes Final Extension 
4ºC undetermined Pause 
 
Finally, sequencing products were purified using IIlustra Sephadex® G-50 fine 
[GE Healthcare, Life Sciences, Cleveland, USA], according to standard procedures. After purification, 15 μL 
of Hi-DiTM Formamide [Applied Biosystems] was added to the sequencing products to help stabilize 
the single stranded DNA. Sequencing analysis was performed by capillary electrophoresis 
on a 3500 Genetic Analyser [Applied Biosystems]. Electropherograms were analysed by the 
Sequencing Analysis Software v5.4 [Applied Biosystems] and sequences were manually reviewed 
at least twice. Mutation Surveyor V4.0.8 software [Softgenetics, State College, PA, USA] was used and 
the nomenclature of PPM1D variants were described according to the LRG_770 
(NM_003620.3) and to the Human Genome Variations Society guidelines. 
 
 
  
 
 
 
 
 
 
 
 
 
Results 
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Results 
 
1. PPM1D Mutations 
 
1.1. Somatic Mutations 
 
DNA samples from a series of 326 women (209 diagnosed with BC and 117 
with OC) were screened for mutations in the last coding exon of the PPM1D gene by Sanger 
sequencing. No mutations were found in patients diagnosed with BC. Three truncating 
mutations (Table 7) were detected in two cases diagnosed with OC, which corresponds to 
a frequency of PPM1D somatic mutations of 1.7% (2/117). 
 
Table 7 - Truncating mutations found in the PPM1D gene. 
Sample 
number 
cDNA description Protein description Effect 
#137 c.1344_1350del p.(Asn448LysfsTer7) Frameshift 
#112 
c.1521del p.(Met508TrpfsTer6) Frameshift 
c.1637del p.(Leu546ArgfsTer2) Frameshift 
 
The c.1344_1350del mutation consists of a frameshift deletion of 7 base pairs 
(Figure 7, a.) leading to the downstream formation of a premature stop codon 
(p.Asn448LysfsTer7).  
Additionally, two other frameshift mutations were detected in the same patient: 
the c.1521del that consists in a deletion of a cytosine (Figure 8, a.) in the third position of 
codon 507 (GTC → GT-), resulting in the formation of a premature stop codon 
(p.Met508TrpfsTer6), and the c.1637del mutation that consists in a deletion of a thymine 
(Figure 8, c.) in the second position of codon 546 (CTG → C-G), resulting in a downstream 
premature stop codon (p.Leu546ArgfsTer2).  
These mutations are not described in the literature nor in mutation databases 
such as COSMIC (Catalogue of Somatic Mutations in Cancer) and ExAC (Exome 
Aggregation Consortium Browser). 
Ovarian tumor samples from these two patients were also analyzed and no 
mutations were found in exon 6 of the PPM1D gene (Figure 7 b. and 8 b. d.), suggesting 
that these mutations are mosaic. 
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Figure 7 - DNA sequence electropherograms from a. peripheral blood sample #137 (left) presenting the 
mutation c.1344_1350del, p.(Asn448LysfsTer7)  and b. Ovarian carcinoma from the same patient.  
 
 
Figure 8 - DNA sequence electropherograms obtained from peripheral blood sample #112 presenting the 
mutations (a.) c.1521del p.(Met508TrpfsTer6) and (c.) c.1637del p.(Leu546ArgfsTer2). b.; d. – Ovarian 
carcinoma from the same patient. 
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1.2. Germline Mutations 
 
We detected one germline missense mutation in one patient diagnosed with 
OC, which corresponds to a frequency of 0.9% (1/117). This mutation consists of a 
substitution of a guanine for an adenine (transition, c.1607G>A) in the second position of 
codon 536 (AGG → AAG), resulting in a substitution of an Arginine for a Lysine, 
p.Arg536Lys (Figure 9). This mutation has been described by Cardoso et al. (2016) in three 
patients with early-onset and/or familial/hereditary prostate cancer (Cardoso et al., 2016). 
Additionally, this mutation has also been described in the ExAC. 
DNA samples from 11 relatives of the carrier were available for co-segregation 
studies and the mutation was detected in one of her healthy sons. We did not found this 
mutation in the others relatives, including the patient´s brother, who was diagnosed with 
gastric cancer at age 67. 
 
 
Figure 9 - DNA sequence electropherogram obtained from a. peripheral blood sample #40 with the mutation 
c.1607G>A, p.(Arg536Lys). b. Negative control case. 
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2. Clinicopathological Characteristics 
 
Patient #137, which presented the PPM1D mutation c.1344_1340del, 
p.(Asn448LysfsTer7), is a woman who was diagnosed at age 50 years with serous ovarian 
carcinoma. The patient's peripheral blood had previously been tested for mutations in 
BRCA1 and BRCA2 genes and it was negative. After the peripheral blood collection, this 
patient underwent chemotherapy, namely nine cycles with paclitaxel and carboplatin, and 
targeted therapy with bevacizumab. She has a family history of cancer, the father was 
diagnosed with liver cancer and her mother with breast cancer, a maternal grandmother 
with gastric cancer and two cousins, one with prostate cancer and the other with breast 
cancer, diagnosed at age 35 years. (Figure 10, a.). 
Patient #112, presenting the PPM1D mutations c.1521del, p.(Met508TrpfsTer6) 
and c.1637del, p.(Leu546ArgfsTer2), is a woman who was diagnosed at age 56 years with 
poorly differentiated ovarian cancer. She was a carrier of a BRCA2 VUS c.8036A>G, 
p.(Asp1679Gly). Prior to the peripheral blood collection, she was treated with 6 cycles of 
chemotherapy, namely paclitaxel and carboplatin. This patient presented scant family 
history of cancer, with only one maternal uncle diagnosed with colon cancer at age 50 years, 
as it is shown in the pedigree (Figure 10, b.).  
Patient #40, with the PPM1D germline missense mutation c.1607G>A, 
p.Arg536Lys, is a woman who was diagnosed at age 61 years with high grade papillary 
serous ovarian carcinoma. This patient had a personal history of bilateral breast cancer at 
ages 32 and 36 and gastric cancer at age 38. This patient was a carrier of the BRCA1 
germline pathogenic mutation c.441+1724_oNBR1:c.1073+480del, p.? and her family 
history of cancer included: paternal uncle diagnosed with prostate cancer, father and 
brother diagnosed with gastric cancer; mother with ovarian cancer and a half-sister of the 
mother’s side, with breast cancer (Figure 11).  
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Figure 10 - Pedigrees of the two patients positive for mosaic somatic mutations in the PPM1D gene (indicated 
by the arrows): a. patient #137; b. patient #112. 
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Figure 11 - Pedigree of patient #40 (indicated by the arrow) that presented the PPM1D c.1607G>A mutation 
and the BRCA1 c.441+1724_oNBR1:c.1073+480del. Plus and minus signals represent family members with 
and without the PPM1D mutation (black) and BRCA1 mutation (red). 
 
- 
+ 
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Discussion 
 
Several decades of BC and OC research have revealed that these diseases 
cannot be viewed as one cancer entity, but comprise distinct molecular tumor subtypes. 
Germline mutations in the BRCA1/2 genes are responsible for a significant proportion of 
hereditary BC and/or OC and cause the HBOC syndrome. Individuals carrying pathogenic 
BRCA1/2 mutations have a high cumulative risk of developing BC and/or OC, and is 
therefore crucial to identify the families with this syndrome and the causative mutation 
(Antoniou et al., 2003; Chenevix-Trench et al., 2006). Several studies demonstrated that 
other rare genetic variants also contribute to BC and OC predisposition (Gayther and 
Pharoah, 2010; Turnbull and Rahman, 2008). Recently, truncating mutations in PPM1D 
gene were also associated with predisposition to BC and OC (Akbari et al., 2014; Ruark et 
al., 2013). In this study we aimed to investigate the prevalence of the PPM1D mutations in 
patients diagnosed with early-onset BC or with OC, as well as to relate these mutations with 
clinicopathological features and with the treatment received.  
In this work, we found three different somatic truncating mutations in the 
peripheral blood DNA of two patients in a series of 117 OC patients, which corresponds to 
a frequency of PPM1D variants of 1.7% of OC patients. The PPM1D truncating variants that 
we found were the c.1344_1350del, p.(Asn448LysfsTer7); c.1521del, p.(Met508TrpfsTer6) 
and c.1637del, p.(Leu546ArgfsTer2). The Sanger sequencing chromatograms of these 
mutations suggested that they were mosaic in lymphocyte DNA, as the mutant allele was 
considerably lower than the wildtype allele. This was confirmed by their absence in tumor 
DNA from the respective patients, which is in agreement with previous reports (Akbari et 
al., 2014; Ruark et al., 2013). Somatic mosaicism refers to the occurrence of two genetically 
distinct populations of cells within an individual, derived from a postzygotic mutation. In 
contrast to inherited mutations, somatic mosaic mutations may affect only a portion of the 
body and are not transmitted to progeny if germline mosaicism is not present (Freed et al., 
2014). The observed prevalence of PPM1D mosaic somatic mutations in women with OC 
in the present work was somewhat higher than that of other studies (Akbari et al., 2014; 
Pharoah et al., 2016; Ruark et al., 2013). On the other hand, we did not find any PPM1D 
mutation in women diagnosed with early-onset BC, which is compatible with the results of 
Ruark et al. (2013), who described a frequency of 0.26% in 7,781 patients (Ruark et al., 
2013). Possible explanations for the absence of mutations in BC patients are the selection 
criteria, the relatively limited number of cases studied, and the different technique used to 
perform the screening of mosaic PPM1D mutations (Sanger sequencing versus NGS), 
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although the latter is unlikely, given our findings in OC patients using the same methodology 
in fewer cases.  
The initial studies suggested that somatic mosaic PPM1D mutations are 
associated with predisposition to BC and OC. Ruark and collaborators (2013), using pooled 
next-generation sequencing (NGS), analyzed 507 genes implicated in DNA repair in 7,781 
women diagnosed with BC and/or OC, including 773 BRCA1/2 mutation carriers. They 
reported a PPM1D mutation frequency of 0.26% in BC (18/6,912) and 1.07% in OC 
(12/1,121) patients, of which four mutations where detected in BRCA1/2 mutation carriers. 
Additionally, they estimated the relative risk for PPM1D carriers to be 2.7 for BC and 11.5 
for OC. Soon after, Akbari et al. (2014) studied 1,295 women diagnosed with OC, including 
146 BRCA1/2 carriers, for PPM1D exon 6 mutations by NGS. They reported a frequency of 
somatic mosaic PPM1D mutations of 1.5% (20/1,295), none in carriers of BRCA1/2 
mutations, and described that the 12-year mortality of the PPM1D-positive patients was 
higher than PPM1D-negative patients. Furthermore, they also reported that the lifetime risks 
for BC and/or OC among female first-degree relatives of PPM1D mutation carriers were not 
increased when compared with patients without mutations. These observations support the 
hypothesis that PPM1D mutations are not inherited and confirmed the results of Ruark et 
al. (2013). This was the reason why we selected early-onset BC without relevant family 
history for PPM1D mutational analysis, but no mutations were found in this setting.  
So far, all the reported truncating mosaic mutations in PPM1D, found in DNA 
from peripheral blood from cancer patients, are located in the C terminus downstream of 
the catalytic domain, indicating that these mutations are not acting as typical loss-of-function 
mutations (Dudgeon et al., 2013; Ruark et al., 2013; Zajkowicz et al., 2015). Moreover, since 
they are all located in the last exon of the gene, it is plausible that the mutated transcripts 
evade nonsense-mediated mRNA decay (Akbari et al., 2014; Ruark et al., 2013). In fact, 
functional studies revealed that PPM1D somatic mutations enhance TP53 suppression after 
exposure to ionizing radiation, something that led Ruark et al. to propose that these 
mutations lead to a gain-of function effect (Ruark et al., 2013). However, the fact that the 
PPM1D truncating mutations were not found in any of the tumors tested from carriers casts 
doubts about their relevance for cancer predisposition, as in most tumor models the 
predisposing mutation is normally detectable in the tumor tissue. . Different possible 
explanations have been given for the fact that these mutations only appear in DNA from 
peripheral blood and not in tumor cells: First, an ancient PPM1D mutation could have been 
present in the cancer cell of origin, but was subsequently lost, perhaps because PPM1D 
mutation can act as a driver to initiate oncogenesis, but is not required tumor progression; 
Second, the PPM1D mutation could be absent in tumor cells because oncogenesis is driven 
by paracrine factors associated with the mutations in the tumor environment (Emelyanov 
  39 | P a g e  
 
and Bulavin, 2015; Ruark et al., 2013). Large cohorts and/or additional functional evaluation 
are needed to clarify the nature of the truncating mosaic mutations and the risk of 
developing these cancers. 
Recently, two articles suggested that chemotherapy exposure could influence 
the accumulation of these mutations in these patients (Pharoah et al., 2016; Swisher et al., 
2016). It has been demonstrated that chemotherapy agents promote mutagenesis and 
therapy-induced cancers are known to occur (Travis LB, 2001). Pharoah et al. (2016) were 
the first to associate chemotherapy exposure to an increase of PPM1D somatic mutations. 
They sequenced the exon 6 of PPM1D in 3374 epithelial OC and identified 12 mosaic 
variants (0.37%). None of these mutations were identified in patients from whom blood was 
taken prior to disease treatment, leading the authors to suggest that these mutations could 
be influenced by exposure to treatment (Pharoah et al., 2016). Later on, Swisher and co-
workers wished to verify whether PPM1D somatic mosaic mutations reflected a previous 
exposure to chemotherapy, so they selected 412 patients with primary OC and 274 patients 
with platinum-resistant OC. They analyzed the blood DNA through targeted sequencing and 
detected 21 PPM1D mutations in 138 women (15.2%) after 1 regimen of chemotherapy and 
35 mutations in 130 women (26.9%) after 2 regimens. These authors suggested that these 
mutations were strongly associated with prior chemotherapy exposure. However, they also 
found PPM1D mutations in a group of patients who had not been exposed to chemotherapy, 
indicating that there may also be a group of younger, chemotherapy-naive patients with a 
more dominant PPM1D clone (Swisher et al., 2016). Our study supports the suggestion of 
Swisher el at. (2016), since the blood collection from patient #137 was drawn before the 
treatment, whereas the blood collection from patient #112, who harbors two different 
PPM1D mutations, was done after chemotherapy exposure. Looking back at the initial 
studies by Ruark et al. (2013) and by Akbari et al. (2014), all the PPM1D truncating variant 
carriers had been exposed to chemotherapeutic drugs before the time of blood collection. 
Swisher et al. (2016) also reported cases harboring multiple different PPM1D mutations in 
the same individual, something that appeared to be limited to patients with relapsed OC 
who had been treated with more chemotherapy regimens. However, the number of carriers 
in our study is too small to evaluate the association between somatic PPM1D mutations 
and chemotherapy exposure. Larger studies comparing the frequency of PPM1D truncating 
mutations before and after therapy would be useful to clarify if indeed these mutations are 
associated with treatment.  
Swisher et al. (2016) also reported an association between somatic PPM1D 
mutations and age of carriers. This was suggested after observing the differences in the 
mean age in the different subgroups, reporting a consistently older mean age in patients 
with PPM1D mutations than those without mutations (Swisher et al., 2016). Several studies 
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through the years have reported an increasing frequency of clonal somatic mutations with 
age (Barnett, 1997; Jaiswal et al., 2014; Milholland et al., 2015). In our study, the PPM1D 
mutation carriers had an older age at diagnosis (patient #137 was diagnosed at age 50 
years and patient #112 at age 56 years) when compared to the average age of our series 
(mean age 48 years). However, the limited number of mutations reported and the low 
number of patients analyzed in our study do not allow us to draw any conclusions on this 
subject. Be that as it may, the very low average age at diagnosis of BC in our study (32 
years) might also explain why we did not find any mutation using these selection criteria. 
Mosaic TP53 mutations have also been reported in women diagnosed with OC 
and some of them in concomitance with PPM1D mutations (Swisher et al., 2016). Swisher 
and co-workers (2016) reported four somatic mosaic TP53 mutations (1.2%) in patients with 
OC not exposed to previous chemotherapy and seven mutations in patients (2.6%) with 
recurrent, platinum-resistant OC. Contrarily to the PPM1D mutations found by these 
authors, TP53 mutations were not significantly associated with chemotherapy exposure 
neither with age. Long-term prospective studies appear to be required to determine whether 
PPM1D or TP53 somatic mosaic mutations actually confer an increased cancer risk. 
In addition to mosaic somatic mutations, we identified one PPM1D germline 
missense mutation in a patient with a BRCA1 pathogenic mutation, corresponding to a 
frequency of 0.9% of OC patients (1/117). The missense variant c.1607G>A, p.Arg536Lys, 
showed a frequency of germline mutations comparable with that observed in the literature. 
Ruark et al. (2013) reported 16 non-synonymous germline mutations (0.20%) in patients 
with BC and OC (Ruark et al., 2013). Additionally, Cardoso et al. (2016) reported nine 
patients with early-onset and/or familial/hereditary prostate cancer (1.95%) that harbor non 
synonymous germline mutations, with three patients sharing the same missense variant 
found in our study (Cardoso et al., 2016). These authors reported that this mutation 
segregated with the disease in a family member of the proband diagnosed with prostate 
cancer, and suggested that this mutation could have a role in the prostate cancer 
predisposition after in silico analyses and its absence in controls (Cardoso et al., 2016).  
Regarding co-segregation studies, besides the index case with four primary tumors, we only 
had access to DNA from one relative with cancer (brother with gastric cancer, who was not 
a carrier), so it is difficult to distinguish the contribution of the deleterious BRCA1 mutation 
from the eventual effect of this missense PPM1D variant. Since high risk for BC and OC is 
a typical feature of HBOC, the PPM1D variant is not required to explain these cancers of 
index patient. However, there is cancer history from both sides of the family, so it is possible 
that both variants contribute to the overall picture, but only additional segregation studies, 
including the other affected relatives will allow evaluation the contribution of this PPM1D 
missense variant to the risk of developing cancer. 
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 Conclusion and Future Perspectives 
 
It is nowadays recognized that rare genetic variations are an important factor to 
breast and ovarian cancer predisposition. After the completion of this study, we conclude 
that: 
- Mosaic somatic PPM1D truncating mutations do not play a significant role for 
early-onset breast cancer. 
- Mosaic somatic PPM1D truncating mutations are present in peripheral blood 
of 1.7% of patients with ovarian cancer, but not in the respective tumor cells.  
- A germline PPM1D missense mutation was detected in a patient with ovarian 
cancer who also was carrying a deleterious BRCA1 mutation. 
- The pathogenic mechanism and the role of chemotherapy exposure for 
PPM1D mosaic mutations needs further studies. 
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